| Literature DB >> 33328981 |
Jiah Ning Tan1, Shamin Mohd Saffian2, Fhataheya Buang1, Zakiah Jubri3, Ibrahim Jantan4, Khairana Husain1, Norsyahida Mohd Fauzi1.
Abstract
Background: Gynura species have been used traditionally to treat various ailments, such as fever, pain, and to control blood glucose level. This systematic review critically discusses studies regarding Gynura species that exhibited antioxidant and anti-inflammatory effects, thus providing perspectives and instructions for future research of the plants as a potential source of new dietary supplements or medicinal agents.Entities:
Keywords: Gynura; anti-inflammatory; antioxidant; medicinal; plant; reactive oxygen species
Year: 2020 PMID: 33328981 PMCID: PMC7734347 DOI: 10.3389/fphar.2020.504624
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1The flowchart shows the selection process of (A) the journal articles, (B) university dissertations, and theses in this systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline.
Quality assessment of studies on the antioxidant and anti-inflammatory effects of Gynura species.
| Study | Species stated in article | Plant source | Authenticated species | Quality control reported? | Chemical analysis reported? |
|---|---|---|---|---|---|
|
|
| Department of Pharmacognosy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand | − | No | No |
|
|
| Penang Island, Malaysia | + | No | No |
|
|
| Specialty Natural Products Co. Ltd., Thailand | + | No | Yes—HPLC, electrospray ionization time-of-flight mass spectrometry |
|
|
| Ethno Resources Sdn Bhd, Malaysia | + | No | No |
|
|
| Green House Facility, Faculty of Science and Technology, Universiti Kebangsaan Malaysia (UKM) | + | No | No |
|
|
| Hainan Province, South China | + | No | Yes—GC-MS |
|
|
| Jing’an, Jiangxi Province, China | − | No | Yes—ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry |
|
|
| Semenyih, Selangor, Malaysia | + | No | Yes—LC-MS/MS |
|
|
| Brightmark Sdn. Bhd, Semenyih, Malaysia | + | No | No |
|
|
| Shanxi Jintai Biol, China | − | No | Yes—LC-MS/MS |
|
|
| Net house located in the Malaysia Agricultural, Research and development institute (MARDI) | + | No | Yes—1H NMR spectroscopy |
|
|
| Yuanshan Village, Ilan, Taiwan | + | No | Yes—HPLC |
|
|
| Farms in Puli Town, Nanton county, Taiwan | + | No | No |
|
|
| Farms in Puli Town, Nanton county, Taiwan | + | No | No |
|
|
| Farms, unknown location | − | No | No |
|
|
| Farms, unknown location | − | No | No |
|
|
| Farmland in north-eastern part of Thailand, mainly in Buriram province | + | No | No |
|
|
| Not stated | − | No | Yes—electrospray ionization-mass spectrometry, 1H NMR, 13C NMR, 2D-NMR |
|
|
| Not stated | − | No | No |
|
|
| Koeng Sub-district, Mueang District, Maha Sarakham province, Thailand | + | No | Yes—HP-TLC, HPLC, LC-MS/MS |
|
|
| Jabatan Pertanian Relau, Penang, Malaysia | + | No | No |
|
|
| Yogyakarta, West Java, Indonesia | + | No | Yes—HPLC |
|
|
| Suburb of Shanghai, China | + | No | Yes—HPLC |
|
|
| Kendua under Netrokona district of Bangladesh | + | No | Yes—method not stated |
|
|
| Silk Biotechnology Laboratory, Soochow University, Suzhou, China | − | No | No |
|
|
| Silk biotechnology Lab, Soochow University, Suzhou, China | − | No | Yes—HPLC |
|
|
| Plant greenhouse of Longyan University, Longyan, China | − | No | No |
HPLC, high-performance liquid chromatography; +, includes a voucher specimen; −, a voucher specimen is missing.
Risk of bias assessment of each individual study on Gynura species according to OHAT guideline.
| Domain | Questions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selection bias | 1. Was administered dose or exposure level adequately randomized? | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 2 |
| 2. Was allocation to study groups adequately concealed? | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Performance bias | 5. Were experimental conditions identical across study groups? | 2 | 2 | 3 | 1 | 1 | 2 | 3 | 2 | 1 | 2 | 2 | 2 | 3 | 1 | 2 | 1 | 2 | 3 | NR | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 3 |
| 6. Were the research personnel and human subjects blinded to the study group during the study? | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Attrition/exclusion bias | 7. Were outcome data complete without attrition or exclusion from analysis? | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Detection bias | 8. Can we be confident in the exposure characterization? | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 9. Can we be confident in the outcome assessment? | 4 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | |
| Selective reporting bias | 10. Were all measured outcomes reported? | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Other sources of bias | 11. Were there no other potential threats to internal validity (e.g., statistical methods were appropriate and researchers adhered to the study protocol)? | 3 | 1 | 4 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 4 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 2 | 1 | 4 | 1 | 2 | 1 |
1Definitely low risk of bias.
2Probably low risk of bias.
3or NR Probably high risk of bias or Not Reported.
4Definitely high risk of bias.
List of studies on the antioxidant effects of genus Gynura.
| Plant species | Part, | Cell line/Animal study model | Concentration/dose, control groups | Parameter measured and technique used | Findings | Reference |
|---|---|---|---|---|---|---|
|
| Leaf | Human HaCaT keratinocytes | 1, 10, 50 μg/ml | Intracellular ROS production level by dichlorofluorescein (DCF) content | GP extract treatment inhibited UV-induced ROS generation levels about 36% at 50 μg/ml |
|
| Control groups | ||||||
| Normal control | ||||||
| Model control (UV 40 mJ/cm2) | ||||||
| Reference group (50, 100, 200 μg/ml vitamin C) | ||||||
| Extract (ethanol) | ||||||
| | ||||||
| Leaf | Mice normal liver cell line NCTC-1469 | 80 and 160 μg/ml (24 h) | Intracellular ROS production level | ↓ ROS level by 80 and 160 μg/ml GP extract |
| |
| Control groups | ||||||
| Normal control (culture medium) | ||||||
| Extract (aqueous) | ||||||
| Model control (pre-treated with 0.25 mM palmitic acid (PA) + 0.5 mM oleic acid for 24 h) | ||||||
| | ||||||
| Leaf | 18 sprague-dawley rats (6 rats/group) | 1.0 g/kg body weight | Plasma lipid peroxidation levels using thiobarbituric acid reactive substances (TBARS) assay | ↓ plasma TBARS level |
| |
| Oral route | ||||||
| Extract (methanol) | | Daily single dose for 14 days | ||||
| TAS values of rats fed with the extract (1 g/kg) for 14 days followed by CCl4 administration were comparable to values of control group | ||||||
| Control groups | Plasma total antioxidant status (TAS) | |||||
| Normal control | ||||||
| Model control (single dose of CCl4) | ||||||
| Leaf | 30 adult male sprague-dawley rats (6 rats/group) | 250 and 500 mg/kg body weight | Lipid peroxidation levels using TBARS assay | ↑ GST and SOD activities in treated rats (250 and 500 mg/kg) |
| |
| Oral route | ||||||
| Daily for 10 weeks | Glutathione-S-transferase (GST) activity | |||||
| Superoxide dismutase (SOD) activity | ||||||
| Control groups | ||||||
| Normal control (normal saline subcutaneous injections, 10% tween 20 oral administration) | ||||||
| | ||||||
| ↓ MDA level in treatment groups 250 and 500 mg/kg GP. | ||||||
| Carcinogen group (azoxymethane (AOM) subcutaneous injection +10% tween 20 oral administration) | ||||||
| Reference group (AOM, fluorouracil intraperitoneal injection) | ||||||
| Extract (ethanol) | ||||||
| Whole plant | 48 female sprague-dawley rats (6 rats/group) | 250 and 500 mg/kg body weight | Plasma malondialdehyde (MDA) level using high-performance liquid chromatography (HPLC) | ↓ MDA level in treatment groups 250 and 500 mg/kg GP compared to postmenopausal control group at month 3 and month 6 |
| |
| ↑ SOD, GSH-Px and CAT enzyme activities in treated rats (250 and 500 mg/kg) compared to postmenopausal control group. GP maintained SOD activity from month 3 to month 6 | ||||||
| Oral route | ||||||
| Extract (ethanol) | ||||||
| Daily for 24 weeks | ||||||
| | Superoxide dismutase (SOD) activity | |||||
| Glutathione peroxidase (GSH-Px) activity | ||||||
| Control groups | ||||||
| Sham group (rats received basal diet) | ||||||
| Postmenopausal (PM) group (rats subjected to ovariectomy, received 2% cholesterol diet fortified with five-time heated palm oil (5HPO) | ||||||
| catalase (CAT) activity | ||||||
| Positive control (10 mg/kg atorvastatin) | ||||||
| Leaf | 32 male C57BL/6 J mice (8 mice/group) | 500 and 1,000 mg/kg body weight | Hepatic malondialdehyde (MDA) level | ↓↓ MDA level in treatment groups 500 and 1,000 mg/kg GP. |
| |
| Extract (aqueous) | Oral route | |||||
| Glutathione peroxidase (GSH-Px) activity | ||||||
| | ||||||
| ↑↑ GSH-Px, CAT and HO-1 activities in treated mice (500 and 1,000 mg/kg) | ||||||
| Daily for 6 weeks | ||||||
| catalase (CAT) activity | ||||||
| Control groups | ||||||
| Heme oxygenase 1 (HO-1) activity | ||||||
| Normal control (methionine- and choline-sufficient (MCS) diet) | ||||||
| Model control (methionine- and choline-deficient (MCD) diet) | ||||||
|
| Leaf | Human umbilical vein endothelial cells | Aqueous or ethanol extract at 1, 2 or 4% (v/v) | ROS production level by 2′,7′-dichlorofluorescein (DCF) content | Pre-treatments with aqueous or ethanol extract dose-dependently ↓ ROS level and preserved GSH content |
|
| Extract (aqueous, ethanol) | ||||||
| 12 h pre-treatment | ||||||
| catalase (CAT) activity | ||||||
| Pre-treatment at 2 and 4% retained CAT and GSH-Px activities | ||||||
| | ||||||
| Control groups | ||||||
| Glutathione (GSH) content | ||||||
| Control (5.5 mM glucose) | ||||||
| Glutathione peroxidase activity (GSH-Px) | ||||||
| Model control (33 mM glucose) | ||||||
| Leaf | PC12 cell line (rat adrenal gland pheochromocytoma) | Aqueous extract at 0.25, 0.5 or 1% | ROS level by 2′,7′-Dichlorofluorescein diacetate (DCFH-DA) | GB pre-treatments ↑ GSH content, ↑ GSH-Px activity, concentration-dependently ↓ ROS level and ↑ catalase activity |
| |
| 48 h pre-treatment | ||||||
| Glutathione level (GSH) | ||||||
| Extract (aqueous) | ||||||
| Control groups | ||||||
| Glutathione peroxidase activity (GSH-Px) | ||||||
| Normal control | CAT activity assay | |||||
| Model control (H2O2 stimulation) | ||||||
| | ||||||
| Leaf | Male C57BL/6 mice (8 mice/group) | 0.25 or 0.5% | Hepatic GSH or GSSG content | 0.25% or 0.5% GB ↑ GSH content, ↓ GSSG, ↓ ROS levels, maintained GSH-Px, GR, and catalase activities |
| |
| Extract (aqueous) | ||||||
| | ||||||
| Glutathione peroxidase activity (GSH-Px) | ||||||
| Oral route | ||||||
| Glutathione reductase (GR) and catalase | ||||||
| 6 weeks | ||||||
| Control groups | ||||||
| Hepatic ROS level using DCFH-DA | ||||||
| Normal control | ||||||
| Liquid diet group (without ethanol) | ||||||
| Ethanol diet group | ||||||
| vivoA | Leaf | 50 male Balb/cA mice (10 mice/group) | 0.25, 0.5, 1% GB diet | ROS level by DCFH-DA | GB at 3 doses |
|
| Oral route | Glutathione level (GSH) | |||||
| 8 weeks | ||||||
| ↑ GSH content, ↑ GPX, ↑ GR, and ↑ catalase activities↓ ROS level in heart and kidney | ||||||
| Glutathione peroxidase activity (GSH-Px) | ||||||
| Control groups | ||||||
| Extract (aqueous) | ||||||
| Glutathione reductase (GR) | ||||||
| Normal control (standard mouse basal diet) | ||||||
| CAT activity assay | ||||||
| Diabetic model control (40 mg/kg BW streptozotocin via i.p. injection for 5 days) | ||||||
| | ||||||
|
| Leaf, stem | 60 male imprinting control region mice (15 mice/group) | Diets with 1.2% and 4.8% GD | Glutathione peroxidase activity (GSH-Px) | 1.2% GD ↑↑ T-SOD levels, ↓↓ |
|
| Oral route | MDA level 4.8% GD | |||||
| Lyophilized into powder | Total superoxide dismutase activity (SOD) | |||||
| ↑↑ GSH-Px level, ↑ T-SOD level, ↓ MDA level | ||||||
| Lipid peroxidation level by MDA level assay | ||||||
| | ||||||
| Daily for 4 weeks | ||||||
| Control groups | ||||||
| Normal control (normal diet) | ||||||
| Diabetic model control (high-fat diet (18% lard, 20% sugar, 3% egg yolk, 59% basal diet) and 100 mg/kg STZ) | ||||||
| Aerial part | Male ICR mice (15 mice/group) | Diets with 1%, 5% and 10% GD | Hepatic glutathione peroxidase activity (GSH-Px) | 1% GD: ↑ GSH-Px level, ↑ T-SOD level |
| |
| Lyophilized into powder | ||||||
| | Oral route | |||||
| 5% GD: ↑ GSH-Px level, ↑↑ T-SOD level, ↓ 8-OHdG level | ||||||
| Daily for 4 weeks | Hepatic total superoxide dismutase activity (SOD) | |||||
| Hepatic lipid peroxidation level by MDA level assay | ||||||
| 10% GD: ↑↑ GSH-Px level, ↑ T-SOD level, ↓ MDA level, ↓ 8-OHdG level | ||||||
| Control groups | ||||||
| Normal control (normal chow) | ||||||
| Hepatic 8-hydroxy-2′-deoxyguanosine (8-OHdG) level using ELISA | ||||||
| Model control (high-fat diet (18% lard, 20% sugar, 3% egg yolk and 59% basal diet) and 100 mg/kg STZ) | ||||||
|
| Leaf | Polymorphonuclear cells neutrophils (PMN) | Extract: 6.25–100 μg/ml | ROS production level by luminol method | GS extract exhibited inhibitory activity upon activation by PMA (IC50 = 1.41 ± 0.63 μg/ml) and zymosan (IC50 = 2.63 ± 0.89 μg/ml) |
|
| Compounds: 3.125–50 μg/ml | ||||||
| Control groups | ||||||
| Negative control (without sample) | ||||||
| 8,8′-(ethene-1,2-diyl)-dinaphtalene-1,4,5-triol revealed ROS inhibitory upon activation by PMA (IC50 = 0.13 μM) and zymosan (IC50 = 0.05 μM) | ||||||
| Extract (methanol), isolated compounds from extract | ||||||
| | ||||||
| Positive control (acetylsalicylic acid) | ||||||
| Rutin inhibited ROS activated by PMA (IC50 = 0.08 μM) and zymosan (IC50 = 0.13 μM) | ||||||
|
| Leaf | H9c2 cardiomyoblasts | 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100 μM | Intracellular ROS production by DCF content | Compound 6 (3,5-dicaffeoylquinic acid ethyl ester) exhibited a more potent cytoprotective effect thus selected for further evaluation |
|
| 1 h pre-treatment | ||||||
| Control groups | ||||||
| | ||||||
| Nine caffeoylquinic acid analogs (1–9) isolated from ethanol extract | ||||||
| CAT activity assay | ||||||
| ↓↓↓ ROS production in H2O2-treated cells, even at a concentration of 0.78 μM | ||||||
| Normal control | ||||||
| Model control (0.3 mM H2O2) | ||||||
| ↑↑↑ H2O2-induced decrease in CAT activity at doses of 25 and 50 μM | ||||||
|
| Leaf | 48 male sprague-dawley rats (8 rats/group) | 100 mg/kg, 250 mg/kg, 500 mg/kg body weight | CAT activity assay | 250 and 500 mg/kg GF treatment ↑↑ activities of CAT, ↑↑ SOD, ↑↑ GSH and ↓↓ lipid peroxidation in rat liver |
|
| Total superoxide dismutase activity (SOD) | ||||||
| Oral route | ||||||
| | Once daily for 7 days | Glutathione level (GSH) | ||||
| Lipid peroxidation level | ||||||
| Control groups | ||||||
| Extract (ethyl acetate) | ||||||
| Normal control | ||||||
| Model control (0.5% carboxymethylcellulose, 1 ml/kg) | ||||||
| Standard drug (4 mg/kg indomethacin) |
↑ indicates significantly induce (p < 0.05), ↑↑ indicates significantly induce (p < 0.01), ↑↑↑ indicates significantly induce (p < 0.001), ↓ indicates significantly inhibit (p < 0.05), ↓↓ indicates significantly inhibit (p < 0.01), and ↓↓↓ indicates significantly inhibit (p < 0.001).
FIGURE 2A schematic illustrating the proposed signaling pathways of the antioxidant and anti-inflammatory effects of Gynura species. The antioxidant effects of Gynura are manifested by the inhibition of reactive oxygen species (ROS) production, suppression of lipid peroxidation, modulation of enzymatic antioxidant production or activities, and modulation of glutathione-related parameters. The reported anti-inflammatory effects of Gynura are modulation of inflammatory cytokines and molecule production as well as inhibition of cellular inflammation and inflammation in an animal model. The potential anti-inflammatory signaling pathways of Gynura include the induction of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt), nuclear factor erythroid 2-related factor 2 (Nrf2), and peroxisome proliferator-activated receptor gamma (PPARγ) signaling pathways as well as the inhibition of the nuclear factor kappa B (NF-κB), glycogen synthase kinase 3 (GSK3), and mitogen-activated protein kinase (MAPK) signaling pathways. Dark blue arrow lines indicate activation, dark blue perpendicular lines indicate inhibition, green tick indicates induction by Gynura species, and red cross indicates suppression by Gynura species.
List of studies on the anti-inflammatory effects of genus Gynura.
| Plant species | Part, | Cell line/Animal study model | Concentration/dose, control groups | Parameter measured and technique used | Findings | Reference |
|---|---|---|---|---|---|---|
| Gynura procumbens (Lour.) Merr. | Leaf | Human HaCaT keratinocytes | 100, 500 μg/ml (24 h) | IL-6 and IL-8 production level using ELISA | By 100 and 500 μg/ml GP extract, IL-6 and IL-8 were inhibited. |
|
| Extract (Ethanol) | Human dermal fibroblasts (HDFs) | 1, 10, 20 μg/ml (48 h) | MMP-1 expression using western blotting | |||
| | Control groups: | MMP-9 expression using Zymography | GP extract dose-dependently inhibited MMP-1 and MMP-9 expression in UV-B irradiated HDFs. | |||
| Normal control | ||||||
| Model control (UV 40 mJ/cm2) | ||||||
| Positive control (10 μM Retinoic acid) | ||||||
| Leaf, stem | RAW 264.7 macrophages | GPEO: 0.003, 0.01, 0.03 μg/ml | Inhibition on inflammatory cell infiltrates using migration assay | GPEO ↓↓↓ LPS-induced cell migration. Limonene, but not α-pinene, 3-carene, or their components mixture, ↓↓↓ cell migration. |
| |
| Essential oil and its active ingredients | | Active ingredients: concentration not stated | ||||
| Treatment time not stated | ||||||
| Control groups: | ||||||
| Normal control | ||||||
| Model control (LPS) | ||||||
| Extract (Ethanol) | | 0.4, 0.6, 0.8 mg/ml | TNF-α and IL-6 production level using ELISA | GP extract dose-dependently ↓ IL-6. GP extract at 0.8 mg/ml ↓ TNF-α. Ethyl acetate fraction showed the best inhibitory effect on IL-6 and TNF-α. |
| |
| Fractions (Petroleum ether, ethyl acetate, n-butanol, water) | 24 h incubation with LPS | |||||
| Control groups: | ||||||
| Normal control | ||||||
| Model control (1 μg/ml LPS) | ||||||
| Whole plant | RAW 264.7 macrophages | 3.9, 15.63, 62.5 and 250 μg/ml | Nitric oxide production level using Griess assay | Pre-treatment of 250 μg/ml GP: |
| |
| Extract (Ethanol) | | 1 h pre-treatment | iNOS protein expression using western blotting | ↓ NO production (dose dependent) | ||
| Control groups: | ↓ iNOS protein expression. | |||||
| Normal control | ||||||
| Vehicle control (0.1% DMSO) | ||||||
| Model control (1 μg/ml LPS) | ||||||
| Leaf | Mice normal liver cell line NCTC-1469 | 80 and 160 μg/ml (24 h) | Nrf2 and | 80 μg/ml GP treatment ↑ Nrf2 protein level, ↓ |
| |
| Extract (Aqueous) | | Control groups: | 160 μg/ml GP treatment ↑ Nrf2 protein levels, ↓↓ | |||
| Normal control (Ad-shCtrl) | ||||||
| Model control (pre-treated with Ad-shCFLAR for 24 h) | ||||||
| Leaf | RAW 264.7 macrophages | 15.63, 31.25, 62.5, 125, 250, 500 μg/ml | Nitric oxide production level using Griess assay | GP extract showed anti-inflammatory activity by inhibiting NO production |
| |
| Extract (Ethanol) | | Control groups: | ||||
| Normal control | ||||||
| Model control (IFN-γ + LPS) | ||||||
| Aerial part | Balb/c white mice (5 mice/group) | 0.75 mg/20 μl | Ear thickness (anti-inflammatory activity) | Original organic crude extract ↓↓↓ croton oil-induced ear inflammation. |
| |
| Extract (Ethanol) | | Topical application | ||||
| 30 min pre-treatment, ear thickness was measured at 24 h | ||||||
| Control groups: | ||||||
| Model control (20 μl acetone at left ear + 0.1 mg/20 μl/ear croton oil) | ||||||
| Standard anti-inflammatory agent (hydrocortisone) | ||||||
| Leaf | Male BALB/c mice (5 mice/group) | 50 mg/kg body weight | GSK3β phosphorylation using western blotting | GP ↑ phosphorylation of liver GSK3β (Ser9) compared with non-treated control |
| |
| Extract (Ethanol) | | Intraperitoneally treated | TNF-α, IFN-γ and IL-10 production level using ELISA | ↓ TNF-α and IFN-γ levels in liver and serum by administration of GP | ||
| 1 day pre-infection | ↑ IL-10 level in serum. | |||||
| Control groups: | ||||||
| Normal control | ||||||
| Model control (B. pseudomallei infection) | ||||||
| Leaf, stem | 50 male Kunming mice (5 mice/group) | GPEO: 0.433, 0.865, 1.73 mg/ml | Ear thickness by xylene-induced ear edema | GPEO ↓↓ xylene-induced ear and hind paw edema at all doses throughout experiment. Treatment with active ingredients mixture ↓ ear and hind paw edema. |
| |
| Essential oil and its active ingredients | | Active ingredients: α-pinene (0.174 mg/ml), 3-carene (0.153 mg/ml), limonene (0.036 mg/ml) and mixture of all 3 ingredients | Hind paw edema using micrometre and histological examination | |||
| Topical administration | COX-2 expression using immunohistochemical staining and multispectral imaging analysis | ↓ COX-2 expression by 0.865 mg/ml GPEO and all 3 individual and mixture of active ingredients. | ||||
| Control groups: | ↓↓ COX-2 expression by 1.73 mg/ml GPEO. | |||||
| Untreated control | ||||||
| Model control (topical application of sesame oil + 20 μl xylene, intradermal injection of 20 μl 4% formalin) | ||||||
| Positive control (diclofenac diethylamine emulgel (DDE)) | ||||||
| Leaf | 32 Male C57BL/6J mice (8 mice/group) | 500 and 1,000 mg/kg body weight | Nrf2 and | 500 mg/kg GP treatment ↑ Nrf2 protein level, no obvious effect on |
| |
| Extract (Aqueous) | | Oral route | mRNA expression of PPARγ using RT-qPCR | |||
| Daily for 6 weeks | 1000 mg/kg GP treatment ↑ protein levels of hepatic Nrf2, ↓ protein level of hepatic | |||||
| Control groups: | ||||||
| Normal control (methionine- and choline-sufficient (MCS) diet) | ||||||
| Model control (methionine- and choline-deficient (MCD) diet) | ||||||
| Gynura bicolor (Roxb. ex Willd.) DC | Leaf | RAW 264.7 macrophages | 15, 30, 60, or 120 μg/ml | Nitric oxide production level using Griess assay | ↓ NO production (30% decrease with 120 μg/ml GB) |
|
| Extract (Ether) | | 3 h pre-treatment | PGE2 production using competitive enzyme immunoassay (EIA) kit | ↓ PGE2 production (dose dependent) | ||
| Control groups: | iNOS, COX-2, phosphorylated-IκBα and p65 protein expression using immunoblot analysis | ↓ iNOS and COX-2 protein expressions (concentration dependent) | ||||
| Vehicle control group (0.1% (v/v) methanol) | NF-κB DNA-binding activity by Nuclear protein preparation and electrophoretic mobility shift assay (EMSA | ↓ | ||||
| Model control (1 μg/ml LPS) | ↓ nucleic p65 protein levels (3–41% decrease with 30, 60, 120 μg/ml GB) | |||||
| ↓ translocation of NF-κB from the cytosol to nuclei | ||||||
| ↓ DNA-binding activity of NF-κB nuclear protein by 30, 60, 120 μg/ml GB | ||||||
| Leaf | Human umbilical vein endothelial cells (HUVEC) | Aqueous or ethanol extract at 1, 2 or 4% (v/v) | IL-6 and TNF-α production using cytoscreen immunoassay | Pre-treatments with aqueous or ethanol extract of GB at 2 and 4% |
| |
| Extract (Aqueous, Ethanol) | | 12 h pre-treatment | Prostaglandin E (PGE2) production | ↓ IL-6, TNF-α formation | ||
| Control groups: | Cyclooxygenase (COX)-2 activity | ↓ PGE2 formation | ||||
| Control (5.5 mM glucose) | ↓ COX-2 activity. | |||||
| Model control (33 mM glucose) | ||||||
| Leaf | PC12 cell line (rat adrenal gland pheochromocytoma) | Aqueous extract at 0.25, 0.5 or 1% | LDH activity | ↓ LDH activity in concentration dependent manner |
| |
| Extract (Aqueous) | | 48 h pre-treatment | Mitochondrial membrane potential (Δψm) using fluorescent dye Rh123 | ↑ Δψm in concentration dependent manner | ||
| Control groups: | IL-6, IL-1β and TNF-α production level by cytoscreen assay | ↓ IL-6, IL-1β and TNF-α production level | ||||
| Normal control | NF-κB and p38 mRNA expression using RT-PCR | Test concentrations (0.25, 0.5 and 1%) ↓ NF-κB mRNA expression | ||||
| Model control (H2O2 stimulation) | 0.5 and 1% extract ↓ p38 mRNA expression. | |||||
| Leaf | Male C57BL/6 mice (8 mice/group) | 0.25 or 0.5% G. bicolor aqueous extract diet | Hepatic levels of IL-1β, IL-6 and TNF-α using cytoscreen immunoassay kits | GB dose-dependently ↓ hepatic levels of inflammatory cytokines of IL-1β, IL-6 and TNF-α. |
| |
| Extract (Aqueous) | | Oral route | ||||
| 6 weeks | ||||||
| Control groups: | ||||||
| Normal control | ||||||
| Liquid diet group (without ethanol) | ||||||
| Ethanol diet group | ||||||
| Leaf | 50 male Balb/cA mice (10 mice/group) | 0.25, 0.5, 1% GB diet | Cardiac or renal level of IL-1β, IL-6 or TNF-α using cytoscreen immunoassay kits | GB at 3 doses: |
| |
| Extract (Aqueous) | | Oral route | p38 and NF-κB mRNA expression using RT-PCR | ↓ level of IL-1β, IL-6, and TNF-α in heart and kidney | ||
| 8 weeks | ↓ p38 and NF-κB mRNA expression in heart or kidney | |||||
| Control groups: | ||||||
| Normal control (basal diet) | ||||||
| Diabetic model control (40 mg/kg BW streptozotocin (in citrate buffer, 0.1 M) via i.p. injection for 5 days) | ||||||
|
| Leaf | HeLa cells | 0.2–200 μg/ml | IL-6/luciferase assay (NF-κB assay) |
|
|
| Extract (Methanol, Ethyl acetate, Petroleum ether) |
| 1, 10 and 50 μg/ml | IL-6, IL-1, TNF-α and PGE2 production level using ELISA and EIA | |||
| Monocytes from healthy human donors | 24 h | |||||
| | Control groups: | |||||
| Positive control (ethanol) | ||||||
| Negative control (Unstimulated cells) | ||||||
| Reference group (Parthenolide, hydrocortisone) | ||||||
| Leaf | HeLa cells | Non-toxic concentrations (using the MTT assay) | IL-6/luciferase assay (NF-κB assay) | Quercetin 3-rutinoside showed the highest NF-κB inhibitory effect. |
| |
| Isolated compound from methanol extract | | Control groups: | NF-κB inhibitory activities IC50: | |||
| Positive control (ethanol) | Quercetin 3-rutinoside: 24.1 ± 0.1 μg/ml | |||||
| Negative control (Unstimulated cells) | 3,5-di-caffeoylquinic acid: 42.8 ± 0.2 μg/ml | |||||
| Reference group (Parthenolide) | 4,5-di-caffeoylquinic acid: 49.1 ± 0.1 μg/ml | |||||
| 5-mono-caffeoylquinic acid: 83.0 ± 0.1 μg/ml | ||||||
| Leaf | Human HaCaT keratinocytes | Extract: 375 and 750 μg/ml | IL-8 production level using ELISA | Extract at both tested concentrations and some concentration of each marker compounds: |
| |
| Extract (Ethanol), marker compounds |
| Chlorogenic acid: 140 and 280 μg/ml | RelA and RelB localization by immunofluorescence assay | ↓ IL-8 production level | ||
| Caffeic acid: 30 and 60 μg/ml | ↓ translocation of RelB S573 into nucleus | |||||
| Rutin: 750 and 1,500 μg/ml | ||||||
|
| ||||||
| 24 h | ||||||
| Control groups: | ||||||
| Normal control | ||||||
| Model control (50 ng/ml TNF-α with/without 0.7% DMSO) | ||||||
| Positive control (50 μg/ml curcumin) | ||||||
| Leaf | 25 patients with mild to moderate plaque psoriasis | Mixture of extract and vehicle (1:10) | Phosphorylation of NF-κB p65 using immunohistochemistry (skin sections from two patients) | Immunohistochemical staining revealed diminution of phosphorylated NF-κB p65 in the lesions treated with the GP ointment. |
| |
| Ointment from ethanol extract | Randomized controlled study | Twice daily for 4 weeks | ||||
| Control: 0.1% triamcinolone cream | ||||||
|
| Leaf, stem | 60 male imprinting control region mice (15 mice/group) | Diets with 1.2 and 4.8% GD | Pancreatic Akt, PI3K, and PDK-1 mRNA expressions using qPCR | 1.2% GD: |
|
| Lyophilized into powder |
| Oral route | Pancreatic | ↑ Akt mRNA, ↑ | ||
| Daily for 4 weeks | ||||||
| Control groups: | 4.8% GD: | |||||
| Normal control (Normal diet) | ↑↑ Akt mRNA, ↑↑ | |||||
| Diabetic model control (high-fat diet (18% lard, 20% sugar, 3% egg yolk, 59% basal diet) and 100 mg/kg STZ) | ||||||
| Aerial part | Male ICR mice (15 mice/group) | Diets with 1, 5 and 10% GD | Western blotting to determine hepatic protein expression of | 1% GD: ↑ |
| |
| Lyophilized into powder | | Oral route | phosphatidylinositol 3-kinase (PI3K) | |||
| Daily for 4 weeks | phosphorylated protein kinase B ( | |||||
| Control groups: | phosphorylated glycogen synthase kinase 3β ( | 5% GD: ↑ PI3K, ↑ | ||||
| Normal control (Normal chow) | PPARγ | |||||
| Model control (high-fat diet (18% lard, 20% sugar, 3% egg yolk and 59% basal diet) and 100 mg/kg STZ) | Tumor necrosis factor-α (TNF-α) | 10% GD: ↑ PI3K, ↑↑ | ||||
| Nuclear factor kappa B (NF-κB) | ||||||
|
| Leaf | RAW 264.7 macrophages | Extract: 6.25–100 μg/ml | Nitric oxide production level using Griess assay | GS extract showed inhibition on NO production with IC50 = 0.16 ± 0.03 μg/ml 8,8′-(ethene-1,2-diyl)-dinaphtalene-1,4,5-triol depicted the strongest NO inhibitory activity with IC50 value of 0.15 μM. |
|
| Extract (Methanol), isolated compound from extract | Peripheral blood mononuclear cells (PBMCs) | Compounds: 3.125–50 μg/ml | IL-1β and TNF-α production level using ELISA | GS extract showed IC50 TNF-α = 16.20 ± 3.94 μg/ml; IC50 IL-1β = 2.72 ± 1.84 μg/ml 4,5,4′-trihydroxychalcone demonstrated the highest inhibition on IL-1β release (IC50 = 6.69 μM). Rutin was the most potent sample against TNF-α release with IC50 = 16.96 μM. |
| |
| | 3 h (Griess assay) or 12 h pre-treatment (ELISA) | |||||
| Control groups: | ||||||
| Positive control (0.025 μM Dexamethasone) | ||||||
| Male Sprague-Dawley rats | 125, 250 and 500 mg/kg body weight | Cotton pellet granuloma assay | GS dose-dependently ↓↓↓ formation of granuloma tissues (17.1, 39.7, and 47.2% inhibition by 125, 250 and 500 mg/kg GS), ↓↓↓ TNF-α and IL-1 levels in circulating pro-inflammatory cytokine levels. | |||
| Extract (Methanol) | | Oral route | TNF-α and IL-1 production level using ELISA | |||
| Once daily for 7 days | ||||||
| Control groups: | ||||||
| Negative control (1% Tween 80) | ||||||
| Reference group (5 mg/kg indomethacin) | ||||||
|
| Leaf | H9c2 cardiomyoblasts | 1.56, 3.12, 6.25, 12.5, 25, 50, 100 μM | LDH production level | Compound 6 (3,5-dicaffeoylquinic acid ethyl ester) exhibited a more potent cytoprotective effect thus selected for further evaluation. |
|
| Nine caffeoylquinic acid analogs (1–9) isolated from ethanol extract | | 1 h pre-treatment | Mitochondrial membrane potential (Δψm) | ↓ LDH leakage at 6.25, 12.5, 25, 50 and 100 μM compound 6. | ||
| Control groups: | Phosphorylation of ERK, JNK, and p38 | ↑↑↑ Δψm in cells cultured with compound 6 (6.25, 12.5, 25.0 μM). | ||||
| Normal control | ↓ Phosphorylation of JNK and ERK by 12.5 and 25.0 μM compound 6 | |||||
| Model control (0.3 mM H2O2) | ||||||
| Positive control (Carbonyl cyanide | ||||||
| Leaf | 24 Swiss albino mice (6 mice/group) | 250 and 500 mg/kg body weight | Xylene-induced ear edema test | 250 and 500 mg/kg GN extract ↓ xylene-induced ear edema and carrageenan-induced models of inflammation. |
| |
| Extract (Ethanol) | | Oral route | Carrageenan-induced paw edema test | |||
| 1 h before infection | ||||||
| Control groups: | ||||||
| Model control (distilled water + 20 μl xylene, saline + injection of 0.1 ml 1% carrageenan) | ||||||
| Positive control (100 mg/kg diclofenac sodium) | ||||||
|
| Leaf | 48 male Sprague-Dawley rats (8 rats/group) | 100 mg/kg, 250 mg/kg, 500 mg/kg body weight | Cotton pellet granuloma assay | GF dose-dependently ↓ granuloma formation. |
|
| Extract (Ethyl acetate) | | Oral route | LDH, GPT, CRP, TNF-α and IL-1β production level using ELISA | 100, 250, and 500 mg/kg GF ↓ levels of plasma inflammatory biomarkers (LDH, GPT and CRP) activities. | ||
| Once daily for 7 days | ||||||
| Control groups: | GF dose-dependently ↓ plasma pro-inflammatory cytokines (TNF-α and IL-1β). | |||||
| Normal control | ||||||
| Model control (0.5% carboxymethylcellulose, 1 ml/kg) | ||||||
| Standard drug (4 mg/kg indomethacin) |
↑ indicates significantly induce (p < 0.05), ↑↑ indicates significantly induce (p < 0.01), ↑↑↑ indicates significantly induce (p < 0.001), ↓ indicates significantly inhibit (p < 0.05), ↓↓ indicates significantly inhibit (p < 0.01), and ↓↓↓ indicates significantly inhibit (p < 0.001).
Phytochemicals of Gynura species.
| Species | Identified phytochemicals | References |
|---|---|---|
|
| 15,16-Dihydroxy-9Z, 12Z-octadecadienoic acid (PubChem CID: 16061068) |
|
| 3,4-Dicaffeoylquinic acid (Isochlorogenic acid B) (PubChem CID: 5281780) | ||
| 3,5-Dicaffeoylquinic acid (Isochlorogenic acid A) (PubChem CID: 6474310) | ||
| 3,5-O-Dicaffeoylquinic acid (PubChem CID: 13604688) | ||
| 3-O-Methyl gallic acid sulfate (PubChem CID: not found) | ||
| 3-Carene (PubChem CID: 26049) | ||
| 4,5-Dicaffeoylquinic acid (Isochlorogenic acids C) (PubChem CID: 6474309) | ||
| 4-O-Methyl gallic acid sulfate (PubChem CID: not found) | ||
| 5-O-(E)-Caffeoyl-galactaric acid (PubChem CID: not found) | ||
| Apigenin (PubChem CID: 5280443) | ||
| Caffeic acid (PubChem CID: 689043) | ||
| Chlorogenic acid (PubChem CID: 1794427) | ||
| Choline (PubChem CID: 305) | ||
| Citric acid (PubChem CID: 311) | ||
| Cynarine (PubChem CID: 5281769) | ||
| Dicaffeoylquinic acids (PubChem CID: 6474310) | ||
| Eriocitrin (PubChem CID: 83489) | ||
| Ferulic acid (PubChem CID: 445858) | ||
| Feruloylquinic acid (PubChem CID: 10133609) | ||
| Gallic acid (PubChem CID: 370) | ||
| Genkwanin isomer (PubChem CID: 5281617) | ||
| Isobioquercetin (PubChem CID: not found) | ||
| Kaempferol (PubChem CID: 5280863) | ||
| Kaempferol 3-O-glucoside (Astragalin) (PubChem CID: 5282102) | ||
| Kaempferol 3-O-rhamnosyl-(1→6)-glucoside (PubChem CID: not found) | ||
| Kaempferol-3-O-rutinoside (Nicotiflorin) (PubChem CID: 5318767) | ||
| Limonene (PubChem CID: 22311) | ||
| Malic acid (PubChem CID: 525) | ||
| Myricetin (PubChem CID: 5281672) | ||
| Neochlorogenic acid (PubChem CID: 5280633) | ||
| Oxooctadecanoic acid (PubChem CID: 439332) | ||
|
| ||
|
| ||
|
| ||
| Phenylalanine (PubChem CID: 6140) | ||
| Protocatechuic acid (PubChem CID: 72) | ||
| Quercetin (PubChem CID: 5280343) | ||
| Quercetin 3-O-rhamnosyl-(1→2)-galactoside (PubChem CID: 44259099) | ||
| Quercetin 3-O-rhamnosyl-(1→6)-glucoside (PubChem CID: not found) | ||
| Quercetin 3-O-rutinoside (Rutin) (PubChem CID: 5280805) | ||
| Sinapic acid (PubChem CID: 637775) | ||
| Syringic acid (PubChem CID: 10742) | ||
| Trimethyl gallic acid glucuronide (PubChem CID: not found) | ||
| Vanillic acid (PubChem CID: 8468) | ||
| α-Pinene (PubChem CID: 6654) | ||
|
| 3,5-Di-O-caffeoylquinic acid (Isochlorogenic acid A) (PubChem CID: 6474310) |
|
| 3-O-Feruloylquinic acid (PubChem CID: 9799386) | ||
| 3-O- | ||
| 4,5-Di-O-Caffeoylquinic acid (Isochlorogenic acid C) (PubChem CID: 6474309) | ||
| 5-O-Caffeoylquinic acid (Neochlorogenic Acid) (PubChem CID: 5280633) | ||
| 5-O- | ||
| Anthocyanin (PubChem CID: 145858) | ||
| Caffeoyl glucose (PubChem CID: 129715972) | ||
| Citric acid (PubChem CID: 311) | ||
| Dihydro-phellopterin (PubChem CID: not found) | ||
| Gallic acid (PubChem CID: 370) | ||
| Geniposide (PubChem CID: 107848) | ||
| Guanosine (PubChem CID: 135398635) | ||
| Isobavachalcone (PubChem CID: 5281255) | ||
| Kaempferol-3-O-caffeoylate (PubChem CID: not found) | ||
| Kaempferol-3-O-glucoside (Astragalin) (PubChem CID: 5282102) | ||
| Malic acid (PubChem CID: 525) | ||
| Phenylalanine (PubChem CID: 6140) | ||
| Protocatechuate-O-glucoside (PubChem CID: not found) | ||
| Quercetin (PubChem CID: 5280343) | ||
| Quercetin-3-acetylhexose (PubChem CID: not found) | ||
| Quercetin-3-O-galactoside (PubChem CID: 5281643) | ||
| Quercetin-3-O-rutinoside (Rutin) (PubChem CID: 5280805) | ||
| Tryptophan (PubChem CID: 6305) | ||
| Uridine (PubChem CID: 6029) | ||
| β-Carotene (PubChem CID: 5280489) | ||
|
| (+)-Tephropurpurin (PubChem CID: 10047971) |
|
| 1-(9Z-octadecenoyl)-sn-glycero-2,3-cyclic phosphate (PubChem CID: 52922109) | ||
| 1,3,8-Trihydroxy-4-methyl-2,7-diprenylxanthone (PubChem CID: 67261902) | ||
| 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8-methyl-8-(4-methyl-3-penten-1-yl)-2,3-dihydro-4H,8H-pyrano[2,3-f]chromen-4-one (PubChem CID: not found) | ||
| 3,4-Dihydroxycinnamoyl-(Z)-2-(3,4-Dihydroxyphenyl) Ethanol (PubChem CID: 14353342) | ||
| 3,5-Dicaffeoyl quinic acid (Isochlorogenic acid A) (PubChem CID: 6474310) | ||
| 3-O-Caffeoyl-1-O-methylquinic acid (PubChem CID: 131752768) | ||
| 4,5-Dicaffeoyl quinic acid (PubChem CID: 13887346) | ||
| 5-Hydroxy-2′-methoxy-6,7-methylenedioxyisoflavone (PubChem CID: 5491929) | ||
| 5-Caffeoyl quinic acid (Chlorogenic acid) (PubChem CID: 1794427) | ||
| Caffeic acid (PubChem CID: 689043) | ||
| Isochlorogenic acid B (PubChem CID: 5281780) | ||
| Isochlorogenic acid C (PubChem CID: 6474309) | ||
| Kaempferol rutinoside (Nicotiflorin) (PubChem CID: 5318767) | ||
| Quercetin (PubChem CID: 5280343) | ||
| Quercetin 3-rutinoside (Rutin) (PubChem CID: 5280805) | ||
| Stigmasterol (PubChem CID: 5280794) | ||
| β-Sitosterol (PubChem CID: 222284) | ||
|
| 3,4-Dicaffeoylquinic acid (Isochlorogenic acid B) (PubChem CID: 5281780) |
|
| 3,5-Dicaffeoylquinic acid (Isochlorogenic acid A) (PubChem CID: 6474310) | ||
| 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) (PubChem CID: 6474309) | ||
| 3-Caffeoylquinic acid (Chlorogenic acid) (PubChem CID: 1794427) | ||
| Cubenol (PubChem CID: 519857) | ||
| Spathulenol (PubChem CID: 92231) | ||
|
| Rutin (PubChem CID: 5280805) |
|
| Gallic acid (PubChem CID: 370) | ||
| 4,5,4′-Trihydroxychalcone (PubChem CID: 468135) | ||
| 8,8'-(Ethene-1,2-diyl)-dinaphtalene-1,4,5-triol (PubChem CID: not found) | ||
|
| 3,4-Dicaffeoylquinic acid methyl ester (PubChem CID: not found) |
|
| 3,5-Dicaffeoylquinic acid ethyl ester (PubChem CID: not found) | ||
| 3,5-Dicaffeoylquinic acid methyl ester (PubChem CID: 10075681) | ||
| 3-O-cis- | ||
| 4,5-Dicaffeoylquinic acid methyl ester (PubChem CID: not found) | ||
| Chlorogenic acid (PubChem CID: 1794427) | ||
| Isochlorogenic acid A (PubChem CID: 6474310) | ||
| Isochlorogenic acid B (PubChem CID: 5281780) | ||
| Isochlorogenic acid C (PubChem CID: 6474309) | ||
| Saponins (PubChem CID: 6540709) | ||
| Tannins (PubChem CID: 250395) |